

INSTITUTIONAL RESEARCH Biotechnology UPDATE REPORT

Member FINRA/SIPC

Toll-Free: 866-928-0928 • www.DawsonJames.com • 101 N. Federal Highway - Suite 600 • Boca Raton, FL 33432

Fortress Biotech (NASDAQ/FBIO)

BUY: Fortress: \$76M in Revenues & \$181M in Cash

Fortress generated consolidated revenues of \$76M last year and closed the year with \$181M in cash and equivalents versus the company's market capitalization of just \$81M.

Investment Highlights

What is Fortress? Fortress today is a company has nine marketed prescription pharmaceutical products as well as 21 plus programs in development by its majority-owned controlled partners. The company also owns significant minority ownership positions in companies. These product candidates run across multiple therapeutic areas from oncology, rare diseases and gene therapy to commercialized dermatology. Fortress creates value through its diversified pipeline combined with a cost-efficient operating structure that fosters efficient drug development.

Potential Revenues and Cashflow Events

Partner Company	Asset(s)	2021	2022	2023	2024	2025	2026+	Potential Peak Sales (Global)
Journey	Commercial Portfolio Qbrexza, Amzeeq, Targadox, etc.	\$63.1M Net revenue	\$73.7M FY2022 Net revenue					
(DERM)	DFD-29 (oral small molecule) Phase 3 readouts for rosacea in H1 2023							00
Caelum*	CAEL-101 (fibril-reactive mAb) Pivotal trials for AL anyloidosis	\$56.9M Monetization				`		000
Checkpoint								000
(CKPT)	Olafertinib (3 rd gen EGFRI) Phase 3 trial in Asia in NSCLC (collaboration)					(Asia)		
Cyprium^	CUTX-101 (copper histidinate) NDA submission for Menkes Disease	\$8M Milestone						٥
	MB-107 (gene therapy) Pivotal Phase 2 trial for newly diagnosed XSCID planned 2023							•
Mustang (MBIO)	MB-207 (gene therapy) Pivotal Phase 2 trial for previously transplanted XSCID planned 2023							•
(mbio)	MB-109 (CAR-T + oneolytic virus) IND filing for GBM planned 2023							00
	MB-106 (CD20 CAR-T) Phase 1/2 multi-center trial ongoing							000
Urica	Dotinurad (URAT1 inhibitor) Phase 1 trial ongoing							000
Anticipated pro	duct revenue/royalties A= Potential PRV	/milestone/moneti	zation proceeds	- 	gulatory approval	©<\$500M ©	© \$500M - \$1B	© © © > \$1B
ORTRESS CMC. Cyprium Is of CMC.	and this threngs are internal estimates based on current knowled are subject to change, "Asset is currently fully controlled by As a, Portress remains eligible to receive up to an additional =3155 surrently in a dispose with the contract manufacturing organization in believes the CMOS grounds for purporting to terminate the with eligible disposed and purport the CMO. To that end, Cyntum or meaning the MSA and portubated the CMO form unities advented.	träzeneca through the ac million in escrow release a (the "CMO"), regarding th A are without ment and is intained a temporary restr	putsition of Caetum, all estim and milectone payments from e CMO's attempt to terminat currently availing itself of at aining order in August 2022	lates and dates related to C in the bransaction. Ie a Master Services Agree appropriate legal remedies and a preliminary insurction	AEL-101 are based on Po ment (together with related in efforts to ensure that th	tress estimates and not gu work orders, the 'MSA') by e CMO abilities by its oblige	Idancé provided by Caelun stween Cyprium and the lions under the MSA ansito	

Source: Fortress

Valuation: How to value Fortress? Fortress is a complex group of companies. Suffice to say; we model the contributions and Fortress holdings in many companies. Our valuation is based on an out-year 2030 share count. For each individual product, we make certain assumptions about the timing and probability of success and apply these assumptions to our model. We apply a probability of success in our therapeutic models. This ranges from as low as 30% to as high as 70% based on what we feel is the therapeutic risk that the product will advance. In addition to the success factor, we apply a 15% discount rate (r) in our Free Cash Flow to the Firm (FCFF), Discounted EPS (dEPS), and Sum of the Parts (SOP) models. We then average the result and round to the nearest whole number to derive our \$24.00 12-month price target.

Risks to our thesis include the following: (1) commercial; (2) regulatory; (3) clinical; (4) financial; and (5) intellectual property. We review these and other risks in the Risk Analysis section of this report.

April 12, 2023

Jason Kolbert Managing Director & Senior Analyst jkolbert@dawsonjames.com

Current Price Price Target			\$0.7 \$24.0
Price target	Late Clinical	Early Clinical	324.0
Commercial			Precincal
Quez#	CUTIX-101	Dotinurad	AN/ATPIAGere Therapy
Anzeeq*	CAEL-101**	A201	in vice CAR T Technology
214*	ME-107	BAER-101	M8-109
Xmind [#]	MB-207	M8-110	OK-103
Exetitent®	DFD-29	MB-101	OK-302
Targadox*	Cosbelinab	MB-102	OK-303
E Manded	Olafertinib	MB-103	AAVsFH Gene Therapy
Uerradog Houcs	Tiplex	MB-104	Cativitax
	N'Tramadoi	MB-105	CEVA-102
	CEVA-101	MB-105	CEVIA-D
		MB-108	1
Therapeutic Area			
Source: Fortress			
Stock Data		60.40	<u>.</u>
52-Week Rang	/	\$0.48 -	\$1.3
Shares Outsta Market Capita			110 \$8
Market Capita Enterprise Val			
Debt to Capita			91
Book Value/Sh			\$1.0
Price/Book	lare		1
,	Months Tradi	ng Volume (K)	22
Insider Owner		ng volume (it)	21.4
Institutional O			17.1
Short interest			0.9
Shore meetese			
Dividend / Yie	ld		50.00/0.0
Dividend / Yie		BIO)	\$0.00/0.0
Fortress	Id Biotech, Inc. (Fl Thousands)	BIO)	\$0.00/0.0 Price (USD)
Fortress Volume (1	Biotech, Inc. (Fi Thousands)		
Fortress Volume (1	Biotech, Inc. (Fi		Price (USD)
Fortress Volume (1	Biotech, Inc. (Fi Thousands)		Price (USD)
Fortress Volume (1	Biotech, Inc. (Fi Thousands)		Price (USD)
Fortress Volume (1	Biotech, Inc. (Fi Thousands)		Price (USD)
Fortress Volume (1	Biotech, Inc. (Fi Thousands)		Price (USD)
Fortress Volume (1	Biotech, Inc. (Fi Thousands)		Price (USD)
Fortress Volume (*	Biotech, Inc. (Fi Thousands)		Price (USD)



Risk Analysis

In addition to the typical risks associated with development-stage specialty pharmaceutical companies, potential risks specific to Fortress Biotech are as follows:

Financial risk. The company may need to raise capital in the marketplace in order to successfully push its products into the next phase, and there can be no assurances that the company will be able to successfully raise capital and/or do so on favorable terms.

Clinical and regulatory risk. Lead products must start and complete clinical trials. Trials may not produce results sufficient for regulatory approval.

Partnership risk. Fortress Biotech may seek partnerships for clinical development support and commercialization. We have no specific knowledge of any discussions with possible partners today, and there can be no assurances that the company will be able to secure a favorable partnership.

Commercial risk. There are no assurances that the company will be able to secure favorable pricing, commercially launch products, and achieve significant market share to become profitable.

Legal and intellectual property risk. The company may have to defend its patents and technical know-how, and there can be no assurances that the patents will not be infringed or will be held as valid if challenged, and or that the company may infringe on third parties' patents.



Exhibit 1. Income Statement

Exhibit 1. Income Statement	00404	00004	00044	00004	10005	20225	20225	4Q23E	00005	20245	00055	00005	00075	0000F	0000F	00005
Probability Revenue Forecast: ('000)	2019A	2020A	2021A	2022A	1023E	2023E	3Q23E	4Q23E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Avenue Therapeutics: IV Tramadol end use sales			\$ -	s -	s - :	\$ - \$		s -	\$ -	\$-	\$ -	\$ -	s -	s -	s -	s -
Percent Owned by Fortress	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%
Revenues Attributed back to Fortress			r - r	-	-	-	-			-	-	-	-	ſ !	ſ !	-
Mustang Bio - Bubble Boy (MB-107)	30%	30%		30%	\$ - 5 30%	\$ - \$ 30%	\$ - \$ 30%		\$ -	\$ 73,125	\$ 101,250	\$ 150,938	\$ 268,125	\$ 255,938	\$ 230,625	\$ 195,000
Percent Owned by Fortress Revenues Attributed back to Fortress	30%	30%	30%	30%	30%	30%	30%	30%	30%	30% 21,938	30% 30.375	30% 45.281	30% 80,438	30% 76,781	30% 69.188	30% 58,500
Cyprium -CUTX-101 - Menkes Disease	v	v	۰ .			s - s	s - s		s .	\$ 21,930	\$ 22,500	\$ 67,500	\$ 112,500	\$ 112,500	\$ 112,500	\$ 112,500
Percent Owned by Fortress	89%	89%	89%	89%	89%	89%	89%	89%	89%	89%	89%	\$ 07,500	89%	\$ 112,500	89%	89%
Revenues Attributed back to Fortress	1	1	1		-	-	-	-	-	-	20,025	60,075	100,125	100,125	100,125	100,125
CheckPoint (Cosibelimab PD-L1)				\$-	\$ -	\$ - \$	\$-\$	s -	\$-	\$-	\$ 94,112	\$ 282,336	\$ 376,448	\$ 470,559	\$ 564,671	\$ 658,783
Percent Owned by Fortress	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%
Revenues Attributed back to Fortress		-	r - 1	-				-	-	-	30,116	90,347	120,463	150,579	180,695	210,811
CK-101 end use sales	0.00/	2004	2004	2001	\$ - 3 32%	\$ - \$ 32%			\$ -	\$ - 000/	\$ 271,206 32%	\$ 542,413 32%	\$ 813,619 32%	\$ 867,861 32%	\$ 922,102 32%	\$ 976,343 32%
Percent Owned by Fortress Revenues Attributed back to Fortress	32%	32%	32%	32%	32%	32%	32%	32%	32%	32%	86,786	173,572		277.715	295,073	32%
Journey Medical Corporation (Dermatology)	34,921	44,531	63,134	65,246	16,507	18,660	17,225	19,378	71,771	78,948	86,842	95,527	105,079	115,587	127,146	139,861
Percent Owned by Fortress	100%	100%	100%	47%	47%	47%	47%	47%	47%	47%	47%	47%	47%	47%	47%	47%
Revenues Attributed back to Fortress	34,921	44,531	63,134	30,666	7,758	8,770	8,096	9,108	33,732	37,105	40,816	44,898	49,387	54,326	59,759	65,734
Other Revenue Back to Fortress	1,708	1,068	5,656	4,254	1,076	1,123	1,170	1,310	4,679	5,147	5,662	6,228	6,851	7,536	8,290	9,119
Fortress Revenues	36,629	45,599	68,791	70,995	8,835	9,893	9,266	10,418	38,412	64,190	213,780	420,402	617,622	667,063	713,128	756,719
														· · · ·	· · · · · ·	
Avenue Therapeutic (IV Tramadol) Royalties (4.5% on sales > \$325M) Associate Milestones			\$-		l											
Mustang Bio - Bubble Boy (MB-107) Prob. Adj. Royalties - 4.5% Associate Milestones				\$-	\$	\$-\$	\$-\$	è -	\$-	\$ 3,290.63	\$ 4,556	\$ 6,792	\$ 12,066	\$ 11,517	\$ 10,378	\$ 8,775
Cyprium - CUTX-101 Menke's Disease - Prob. Adj. Royalties - 4.5% Associate Milestones				\$-		\$ - \$ \$ 2,700 \$			\$ - \$ 10,000	\$ - \$ 10,000	\$ 5,625 \$ 10,000	\$ 16,875 \$ 10,000	\$ 28,125 \$ 10,000		\$ 28,125 \$ 10,000	\$ 28,125 \$ 10,000
CheckPoint (Cosibelmab PD-L1) - Prob. Adj. Royalties - 4.5% Associate Milestones				\$-	s - :	\$-\$	\$-\$	-	\$-	\$-	\$-	\$-	\$ 4,235	\$ 12,705	\$ 16,940	\$ 21,175
CheckPoint (CK-101 - TKI) - Prob. Adj. Royalties -25% Associate Milestones			\$ 2,400		\$ - 5 \$ 11,500	\$ - \$ \$ 13,500 \$	\$-\$ \$11,000 \$	5 - 5 14,000	\$- \$50,000	\$- \$50,000	\$ 12,204 \$ 50,000	\$ 24,409 \$ 50,000	\$ 36,613 \$ 35,000	\$ 39,054 \$ -	\$ 41,495	\$ 43,935
Total Royalties & Milestones			72,666	4,748	13,800	16,200	13,200	16,800	60,000	63,291	82,386	108,076	126,039	101,401	106,938	112,011
Expenses:														(
Fortress														í '	1	
Costs of Goods Sold (Journey Medical) %COGS	10,532 29%	14,594 33%	32,084 51%	30,775 47%	- 0%	- 0%	- 0%	- 0%	0%	- 0%	-0%	- 0%	0%	- 0%	0%	- 0%
Research and Development (Consolidated)	75,236	64,108	113,240	134,199	32,409	33,818	36,636	38,045	140,909	147,954	155,352	163,120	171,276	179,839	188,831	198,273
Fortress	75,230	2,780	113,240	134,199	32,409	33,010	30,030	38,045	140,909	147,954	155,552	103,120	1/1,2/0	179,039	100,031	190,273
Avenue		2,866	-											1 1	1	
Checkpoint		11,735												í '	1	
Mustang		39,475												í '	1	
Journey														i'		
Other**		1,606												1		
Research and Development-licenses acquired	6,090	1,820	15,625	677	163	171	185	192	711	746	784	823	864	907	953	1,000
General and Administrative (Consolidated) Fortress	55,590	61,166 23,341	86,843	113,656	28,982	30,142	26,664	30,142	115,929	118,248	120,613	123,025	125,485	127,995	130,555	133,166
Avenue		23,341												1	1	
Checkpoint		6518												í '	1	
Journey Medical Corp. (SG&A)		25,659												1		
Mustang		6810												1 '	1	
Journey														<u>ا</u>	I'	
Other**		1,184	9540						0.000.010		000 010					
Total Operating expenses Total Operating expenses (Adjusted)	147,448	142,146 69,164	257,332	279,307	61,555	64,130	63,485	68,379	257,549	266,948	276,748	286,968	297,625	308,742	320,339	332,439
Total Operating expenses (Aujusted)		09,104		1					1	1	1	1	1	í '	1	1
Operating Income (Loss)	110,819	(96,546)	(188,541)	(203,564)	(38,920)	(38,037)	(41,019)	(41,161)	(159,137)	(139,468)	19,417	241,510	446,036	459,722	499,727	536,290
	110,019	(23,565)	(100,541)	(200,004)	(30,320)	(30,037)	(41,013)	(41,101)	(155,157)	(133,408)	13,417	241,310	440,030	433,122	400,121	550,230
Operating Income (Loss) adjusted Interest income (expense), net	2,559	(23,565) 2,687	- 649	- 1,398	- 338	-	- 382	- 396	- 1,468	- 1.541	- 1,618	- 1,699	- 1,784	- 1,873	- 1.967	- 2,065
Interest income (expense), net Interest expense and financing fee	2,559 (11,849)	2,687 (12,441)	649 (15,308)	1,398 (13,642)	338 (3,295)	352 (3,438)	382 (3,724)	396 (3,868)	1,468 (14,324)	1,541 (15,040)	1,618 (15,792)	1,699 (16,582)	1,784 (17,411)	1,873 (18,282)	1,967 (19,196)	2,065 (20,155)
Change in FV of derivative liability	(11,049)	(12,441) (1.147)	(15,308) 39,294	(13,042)	(3,293)	(3,430)	(3,724)	(3,008)	(14,324)	(15,040)	(15,792)	(10,082)	(17,411)	(10,202)	(19,196)	(20,100)
Change in FV of subsidiary convertible note	1	(1,147)	(447)										1	í '	1	
Change in FV of investments	(27)	533	()										1	1 '	ł ¹	
Gain on deconsolidation of Caelum	18,476												1	1 '	ł ¹	
Total Other Income	9,159	(10,369)	24,188	(9,900)	(2,957)	(3,085)	(3,343)	(3,471)	(12,856)	(13,499)	(14,174)	(14,883)	(15,627)	(16,408)	(17,229)	(18,090)
Pretax Income (loss from continuing operations)	(101,660)	(130,480)	(164,353)	(213,464)	(41,877)	(41,122)	(44,362)	(44,632)	(171,994)	(152,967)	5,243	226,627	430,409	443,314	482,499	518,200
Income Tax Benefit (Provision) Tax Rate	0%	0%	(447)	449	0%	0%	0%	- 0%	- 0%	(15,297)	786	40,793 18%	86,082 20%	93,096 21%	110,975 23%	129,550 25%
Idx rdie	0%	0%	0%	0%	0%	0%	0%	0%	0%	10%	15%	18%	20%	∠1%	23%	25%
GAAP Net Income (Loss)	(101,660)	(130,480)	(164,826)	(213,913)	(41,877)	(41,122)	(44,362)	(44,632)	(171,994)	(137,670)	4,457	185,834	344,327	350,218	371,524	388,650
Addjusted (Non-GAAP) Loss		(35,842)			(11,011)		(11,002)									
Less: net loss attributable to non-controlling interests	61,700	55,264	100,123	127,338	27,530	28,727	31,121	32,318	119,698	112,516	105,765	99,419	93,454	87,847	82,576	77,621
Net Income (loss) attributable to common stockholders	(39,960)	(53,560)	(64,703)	(86,575)	(14,347)	(12,395)	(13,240)	(12,314)	(52,296)		110,221	285,253	437,781	438,065	454,100	466,271
GAAP-EPS	(0.73)	(0.76)	(0.79)	(0.97)	(0.16)	(0.14)	(0.15)	(0.14)	(0.58)	(0.28)	1.22	3.14	4.80	4.78	4.93	5.05
GAAP-EPS (Dil)	(0.60)	(0.76) (0.50)	(0.79)	(0.97)	(0.16)	(0.14)	(0.15)	(0.14)	(0.58)	(0.28)	1.22	3.14	4.80	4.78	4.93	5.05
Adjusted Nep CAAD EDS (DIL)													1			
Adjusted Non-GAAP EPS (DIL) Watd Ava Shrs (Bas) - '000s	54 714		81 700	88 97F	89 703	89 703	80 883	80 072	80 829	00 109	00.550	00 000	01 290	01.652	02.010	92 397
Wgtd Avg Shrs (Bas) - '000s	54,711 65.502	71,077	81,700 81,700	88,875 88,875	89,703 89,703	89,793 89,793	89,883 89,883	89,973 89,973	89,838 89,838	90,198 90,198	90,559 90,559	90,922 90,922	91,286 91,286	91,652 91,652	92,019 92,019	92,387 92,387
	54,711 65,502		81,700 81,700	88,875 88,875	89,703 89,703			89,973 89,973		90,198 90,198	90,559 90,559	90,922 90,922	91,286 91,286		92,019 92,019	92,387 92,387

* Includes the following partner companies: Aevitas, Cellvation, Oyprium, Helocyte and Tamid (a Fortress partner company that discontinued development and terminated the related licenses and clinical trial agreements with the University of North Carolina at Chapel Mill for all three of its preclinical product candidates).

Source: Dawson James estimates and company reports



Companies mentioned in this report, working with Fortress and/or part of valuation discussion:

Alexion (ALXN/NASDAQ)-Not covered.

Astra Zeneca (AZN/NASDAQ) - Not Covered

InvaGen Pharmaceuticals – (Private).

St. Jude Children's Research Hospital (Private).

Mustang Bio (MBIO/NASDAQ) - Not covered.

Checkpoint Therapeutics (CKPT/NASDAQ) – Not covered.

Avenue Therapeutics (ATXI/ NASDAQ) – Not covered.

Caelum Biosciences (Private).


Journey Medical Corporation (DERM).

Cyprium Therapeutics (Private).

Fuji Yakuhin (subsidiary of Fuji-Japan – Not Covered)

Important Disclosures:

Price Chart:



Price target and rating changes over the past three years: Initiated – Buy August 26, 2019, Price Target \$19.00 Update - Buy September 17, 2019, Price Target \$19.00 Update - Buy November 4, 2019, Price Target \$19.00 Update - Buy December 11, 2019, Price Target \$19.00 Update – Buy December 23, 2019, Price Target \$19.00 Update - Buy January 15, 2020, Price Target \$19.00 Update - Buy February 14, 2020, Price Target \$19.00 Update – Buy February 20, 2020, Price Target \$19.00 Update - Buy March 30, 2020, Price Target \$19.00 Update – Buy May 14, 2020, Price Target \$19.00 Update - Buy July 31, 2020, Price Target \$19.00 Update - Buy September 8, 2020, Price Target \$19.00 Price Target Change - Buy October 12, 2020, Price Target \$15.00 Update – Buy October 20, 2020, Price Target \$15.00 Price Target Change - Buy November 10, 2020, Price Target \$16.00 Update - Buy December 14, 2020, Price Target \$16.00 Update - Buy February 2, 2021, Price Target \$16.00 Price Target Change - Buy February 17, 2021, Price Target \$21.00 Price Target Change - Buy February 24, 2021, Price Target \$22.00



Price Target Change - Buy April 7, 2021, Price Target \$24.00 Update - Buy April 13, 2021, Price Target \$24.00 Update - Buy May 10, 2021, Price Target \$24.00 Update – Buy May 20, 2021, Price Target \$24.00 Update – Buy June 11, 2021, Price Target \$24.00 Update – Buy June 15, 2021, Price Target \$24.00 Update – Buy August 17, 2021, Price Target \$24.00 Update - Buy September 29, 2021, Price Target \$24.00 Update - Buy October 26, 2021, Price Target \$24.00 Update - Buy November 19, 2021, Price Target \$24.00 Update – Buy February 17, 2022, Price Target \$24.00 Update - Buy March 28, 2022, Price Target \$24.00 Update – Buy May 17, 2022, Price Target \$24.00 Update - Buy August 11, 2022, Price Target \$24.00 Update - Buy October 7, 2022, Price Target \$24.00 Update - Buy January 25, 2023, Price Target \$24.00 Update - Buy April 12, 2023, Price Target \$24.00

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has not engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has not received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has not received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of March 17, 2023, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the "VALUATION" and "RISK ANALYSIS" sections of this report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Rating Definitions:

- 1) **Buy**: the analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral**: the analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell**: the analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.



The following chart reflects the range of current research report ratings for all companies, followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

	Company		Investment	
	Coverage		Banking	
				% of
Ratings Distribution	# of Companies	% of Total	# of Companies	Totals
Market Outperform (Buy)	25	69%	1	3%
Market Perform (Neutral)	11	31%	2	6%
Market Underperform (Sell)	0	0%	0	0%
Total	36	100%	3	9%

Current as of	17-Mar-23
---------------	-----------

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.